切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2023, Vol. 17 ›› Issue (12) : 1228 -1232. doi: 10.3877/cma.j.issn.1674-0785.2023.12.005

专题笔谈

外用甲硝唑治疗皮肤病的临床应用
王建波()   
  1. 450003 郑州,河南省人民医院皮肤科
  • 收稿日期:2023-08-14 出版日期:2023-12-15
  • 通信作者: 王建波

Clinical application of topical metronidazole in treatment of dermatosis

Jianbo Wang()   

  1. Department of Dermatology, the People's Hospital of Henan Province, Zhengzhou 450003, China
  • Received:2023-08-14 Published:2023-12-15
  • Corresponding author: Jianbo Wang
引用本文:

王建波. 外用甲硝唑治疗皮肤病的临床应用[J]. 中华临床医师杂志(电子版), 2023, 17(12): 1228-1232.

Jianbo Wang. Clinical application of topical metronidazole in treatment of dermatosis[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(12): 1228-1232.

甲硝唑是硝基咪唑衍生物,具有抗寄生虫、抗菌、抗炎等多重作用,临床应用非常广泛。其中外用甲硝唑制剂是一种常用的皮肤科药物,临床上可用来治疗玫瑰痤疮、痤疮、脂溢性皮炎等皮肤病,不仅疗效显著且安全性好。本文就外用甲硝唑制剂在皮肤科的应用进行系统性回顾。

Metronidazole, a nitroimidazole derivative, has anti-parasitic, antibacterial, anti-inflammatory, and other multiple effects, with very broad clinical applications. Topical metronidazole preparation is a commonly used dermatologic drug for the treatment of rosacea, acne, seborrheic dermatitis, and other dermatologic diseases, which is not only efficacious but also safe. This article is a systematic review of the applications of topical metronidazole in dermatology.

1
汪梦蝶, 夏宇, 侯小龙,等. 甲硝唑与中药在临床上的联合应用情况 [J]. 中南药学,2018,16(3):389-394.
2
杜乐, 喻世静, 殷智鑫,等. 硝基咪唑类药物的研究进展 [J]. 化学世界,2020,61(2):92-98.
3
周圆, 王方, 柯萍,等. 甲硝唑在皮肤科的应用 [J]. 医学综述, 2011,17(8):1207-1209.
4
许蓉. 甲硝唑的不良反应及在临床使用中应注意的问题 [J]. 实用医技杂志,2008,15(13):1684-1685.
5
中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南(2021版) [J]. 中华皮肤科杂志,2021,54(4):279-288.
6
Gether L, Overgaard LK, Egeberg A, et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis [J]. Br J Dermatol, 2018,179(2):282-289.
7
Hampton PJ, Berth-Jones J, Duarte Williamson CE, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021 [J]. Br J Dermatol, 2021,185(4):725-735.
8
Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea [J]. J Eur Acad Dermatol Venereol, 2017,31(11):1775-1791.
9
Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea [J]. J Cutan Med Surg, 2016,20(5):432-445.
10
Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee [J]. J Am Acad Dermatol, 2020,82(6):1501-1510.
11
倪容之, 范志莘. 甲硝唑凝胶治疗酒渣鼻临床疗效观察 [J]. 临床皮肤科杂志,1999(2):49.
12
Miyachi Y, Yamasaki K, Fujita T, et al. Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, vehicle-controlled, phase 3 study [J]. J Dermatol, 2022,49(3):330-340.
13
Tan JK, Girard C, Krol A, et al. Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea [J]. J Cutan Med Surg, 2002,6(6):529-534.
14
Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea [J]. J Am Acad Dermatol, 2001,45(5):723-730.
15
方兴. 甲硝唑凝胶联合多西环素治疗玫瑰痤疮的效果及对患者症状积分的影响 [J]. 中国当代医药,2022,29(22):50-53.
16
Aktaş Karabay E, Aksu Çerman A. Demodex folliculorum infestations in common facial dermatoses: acne vulgaris, rosacea, seborrheic dermatitis [J]. An Bras Dermatol, 2020,95(2):187-193.
17
Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study [J]. J Eur Acad Dermatol Venereol, 2007,21(3):345-350.
18
Siadat AH, Iraji F, Shahmoradi Z, et al. The efficacy of 1% metronidazole gel in facial seborrheic dermatitis: a double blind study [J]. Indian J Dermatol Venereol Leprol, 2006,72(4):266-269.
19
Gupta AK, Versteeg SG. Topical treatment of facial seborrheic dermatitis: a systematic review [J]. Am J Clin Dermatol, 2017, 18(2):193-213.
20
Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review [J]. J Dermatolog Treat, 2019,30(2):158-169.
21
中国痤疮治疗指南专家组. 中国痤疮治疗指南(2019修订版) [J]. 临床皮肤科杂志,2019,48(9):583-588.
22
Akçınar UG, Ünal E, Doğruman Al F. Demodex spp. as a possible aetiopathogenic factor of acne and relation with acne severity and type [J]. Postepy Dermatol Alergol, 2018,35(2):174-181.
23
Zhao YE, Hu L, Wu LP, et al. A meta-analysis of association between acne vulgaris and Demodex infestation [J]. J Zhejiang Univ Sci B, 2012,13(3):192-202.
24
Bannatyne RM. Metronidazole, its bioactive metabolites and acne [J]. Curr Med Res Opin, 1999,15(4):298-299.
25
Khodaeiani E, Fouladi RF, Yousefi N, et al. Efficacy of 2% metronidazole gel in moderate acne vulgaris [J]. Indian J Dermatol, 2012,57(4):279-281.
26
Jain VK, Chopra KL, Dayal S. Comparative evaluation of topical benzoyl peroxide, metronidazole and benzoyl peroxide - clindamycin combination in treatment of acne vulgaris [J]. Indian J Dermatol Venereol Leprol, 1998,64(2):71-74.
27
王钦, 刘安齐, 金智华,等. 复方甲硝唑克林霉素乳膏联合异维A酸治疗轻中度面部寻常型痤疮疗效观察 [J]. 中国药业,2019,28(11):81-84.
28
亚洲干眼协会中国分会, 海峡两岸医药交流协会眼科专业委员会眼表与泪液病学组. 我国蠕形螨睑缘炎诊断和治疗专家共识(2018年) [J]. 中华眼科杂志,2018,54(7):491-495.
29
Ávila MY, Martínez-Pulgarín DF, Rizo Madrid C. Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial [J]. Cont Lens Anterior Eye, 2021,44(3):101326.
30
Arrúa M, Samudio M, Fariña N, et al. Comparative study of the efficacy of different treatment options in patients with chronic blepharitis [J]. Arch Soc Esp Oftalmol, 2015,90(3):112-118.
31
王莎莎, 蒋炎, 黄洁,等. 三种含药眼贴治疗蠕形螨睑缘炎的疗效和安全性评价: 一项多中心双盲随机对照临床试验 [J]. 中华实验眼科杂志,2023,41(5):450-456.
32
Williamson T, Cheng WY, McCormick N, et al. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study [J]. Am Health Drug Benefits, 2018,11(2):97-106.
33
王璐茜, 张昦昉, 王钧,等. 甲硝唑凝胶的皮肤安全性实验研究 [J]. 灾害医学与救援(电子版),2018,7(2):35,49.
[1] 张仙, 程丽琴, 刘小乐. 预防性应用头孢氨苄联合甲硝唑对子宫输卵管造影术后急性盆腔炎性疾病的影响[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(04): 321-325.
[2] 党海波, 乔波, 郭彤彤, 孙畅, 陈祥芳. 背俞穴刺络拔罐疗法治疗寻常痤疮随机对照试验的Meta分析[J]. 中华针灸电子杂志, 2023, 12(02): 74-82.
阅读次数
全文


摘要